RxDoctor Payments Data

Hannah McCall

Family · Covington, GANPI 1376178798

Payments from drug & device makers

$3,599in general payments, 2019–2025

Across 208 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$514
  • Lilly USA, LLC$466
  • AstraZeneca$403
  • Boehringer Ingelheim$369
  • AbbVie$214
  • Pfizer$152
  • plus $1K from 28 others

What the payments were for

  • Food & beverage$3,599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,599 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$69,795
Medicare patients
294
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$64,791
MounjaroTirzepatide26$40,668
JanuviaSitagliptin Phosphate23$29,143
EliquisApixaban27$23,640
JardianceEmpagliflozin17$20,372
TrulicityDulaglutide14$19,621
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,242
LinzessLinaclotide11$6,658
MyrbetriqMirabegron11$6,045
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,703
Breo ElliptaFluticasone/Vilanterol13$5,222
PaxlovidNirmatrelvir/Ritonavir13$4,246
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,624
Levothyroxine Sodium263$2,455
Atorvastatin Calcium199$1,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$514$64,79139 claims
Lilly USA, LLCMounjaro, Trulicity$466$60,28940 claims
MerckJanuvia$13$29,14323 claims
PfizerEliquis, Paxlovid$152$27,88540 claims
Boehringer IngelheimJardiance, Stiolto Respimat$369$26,07529 claims
GSKTrelegy Ellipta, Breo Ellipta$52$17,46428 claims
AbbVieLinzess, Synthroid$214$7,67431 claims
Astellas Pharma US IncMyrbetriq$92$6,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Covington

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →